MP54-14 SEQUENTIAL INTRAVESICAL GEMCITABINE/DOCETAXEL PROVIDES A DURABLE REMISSION IN RECURRENT HIGH RISK NMIBC FOLLOWING BCG THERAPY
Kendrick Yim(Brigham and Women's Hospital), Mark A. Preston(Brigham and Women's Hospital), Timothy N. Clinton, Filipe L.F. Carvalho(Brigham and Women's Hospital), Sarah L. Mott(University of Iowa), Kent W. Mouw(Massachusetts General Hospital), Kevin Melnick(Brigham and Women's Hospital), Graeme S. Steele(Brigham and Women's Hospital), Michael A. O’Donnell(University of Iowa Health Care), Vani Gupta(King George's Medical University), Matthew Mossanen(Massachusetts General Hospital)
Cited by 1
Related Papers
DNA Damage and Repair Biomarkers of Immunotherapy Response
|Cancer Discovery|2017|673
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Formation of Toxic Oligomeric α-Synuclein Species in Living Cells
|PLoS ONE|2008|410
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
|Journal of Surgical Oncology|2014|274
Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study
|BJOG An International Journal of Obstetrics & Gynaecology|1995|215